ClinicalTrials.gg
CompletedNCT01322269Updated Jun 19, 2013

A Study of HQK-1001 in Patients With Sickle Cell Disease

A Phase 2 interventional study of HQK-1001 in Sickle Cell Disease, Sickle Cell Anemia and Sickle Cell Disorders, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 16 sites in 5 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-06-19.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
189th of 559
52 · median 31
Started
2011
with 22 others
Phase 2
161 of 733
23 open now
Registered
165th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 189th largest by enrollment of the 559 interventional ones that give a count, is one of 23 that started in 2011, is one of 161 in phase 2, and was the 165th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Sickle Cell Disorders
  • Hemoglobin S Disease
  • Sickling Disorder Due to Hemoglobin S

Browse trials for

04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of SCD
  • Males and females between 12 and 60 years of age, inclusive
  • At least 3 episodes of a SCD-related crisis or complication in the 3 years prior to screening OR 1 episode of acute chest syndrome in the 5 years prior to screening
  • If receiving hydroxyurea, must be receiving a stable dose for at least 6 months prior to screening
  • If hydroxyurea treatment has been discontinued, at least 3 months have elapsed since last dose
  • If transfusion in the 4 months prior to screening, then HbA level \< 20% at screening
  • Average of the initial two HbF levels ≥ 2.0 % within ≤ 7 days prior to the initial dose of HQK-1001. The two must be obtained ≥ 24 hours apart
  • Ability to swallow tablets
  • Able and willing to give and assent (if applicable)
  • If subject is a woman of (WCBP), she must have a negative serum pregnancy test within 7 days of first dose of HQK-1001
  • If a subject is a WCBP, she must agree to use an effective form of within 7 days of the initial dose of HQK-1001 and for one month after HQK-1001 discontinuation
  • Sexually active male subjects (with WCBP partners) must agree to use latex condoms or ensure that their partner(s) use an effective form of contraception
  • In the view of the Investigator, subject is able and willing to comply with necessary study procedures

Exclusion criteria

Exclusion Criteria:

  • More than 4 hospitalizations for acute sickle cell related events in the previous 12 months prior to screening
  • Pulmonary hypertension requiring oxygen therapy
  • > 450 msec (male) or 470 msec (female) on screening (QT corrected by Fridericia's formula)
  • Assigned to a regular transfusion program
  • Use of erythropoiesis stimulating agents within 90 days of screening
  • > 3x (ULN)
  • Serum creatinine > 1.2 mg/dL
  • A serious, concurrent illness that would limit ability to complete or comply with the study requirements
  • An acute vaso-occlusive event within 3 weeks prior to screening
  • Creatine phosphokinase (CK) > 20% above the ULN
  • An acute illness (e.g., febrile, GI, respiratory) within 72 hours prior to screening
  • History of syncope, dysrhythmias or resuscitation from sudden death
  • Chronic opiate use, which, in the view of the Investigator, could confound evaluation of an drug
  • Current abuse of alcohol or drugs
  • Received another investigational agent within 4 weeks or 5 half-lives, whichever is longer, prior to screening
  • Currently pregnant or breast feeding a child
  • Known infection with -1
  • Infection with or , such that patients are currently on therapy or will be placed on therapy during the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    HQK-1001 (30 mg/kg)

    Drug: HQK-1001

  • Experimental
    HQK-1001 (40 mg/kg)

    Drug: HQK-1001

  • Experimental
    HQK-1001 (50 mg/kg)

    Drug: HQK-1001

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    Physical exams, vital signs, clinical laboratory safety assessments, ECG and adverse event monitoring.

    Time frame: Day 1 through Week 30

Secondary outcomes

  1. Fetal hemoglobin levels

    Time frame: Day 1 and Weeks 4, 8, 12, 16, 20, 25, 26 and 30

  2. Incidence of sickle cell crisis events

    Time frame: Day 1 through Week 30

07

Study locations

16 sites
  • Children's Hospital and Research Center - Oakland
    Oakland, California 94609, United States
  • University of Miami Miller School of Medicine - Dept of Pediatrics
    Miami, Florida 33101, United States
  • Georgia Health Sciences University - Adult SIckle Cell Center
    Augusta, Georgia 30912, United States
  • University of Illinois at Chicago - Dept of Pediatrics
    Chicago, Illinois 60612, United States
  • LSU Health Sciences Center - Feist Weiller Cancer Center
    Shreveport, Louisiana 71103, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • University of North Carolina at Chapel Hill - Comprehensive Sickle Cell Program
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Univerisity of Texas Southwestern Medical Center at Dallas - Pediatric Hematology Oncology
    Dallas, Texas 75390-9063, United States
  • The Hospital for Sick Children
    Toronto, Ontario MSG 1X8, Canada
  • University Health Network Toronto General Hospital
    Toronto, Ontario MSG 2C4, Canada
  • Abu El Reesh Pediatric University Hospital
    Cairo, Egypt
  • University of the West Indies - Sickle Cell Unit
    Mona, Kingston, Jamaica
  • American University of Beirut Medical Center
    Beirut, Lebanon
  • Rafik Hariri University Hospital
    Beirut, Lebanon
  • Chronic Care Center
    Hazmieh, Lebanon
08

References and documents

Publications

  • Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov;88(11):E255-60. doi: 10.1002/ajh.23533. Epub 2013 Oct 3. PubMed 23828223 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011 and a primary completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2011
First posted
Mar 24, 2011
Start
Apr 2011
Primary completionActual
Mar 2012
Results delay requested
Jun 11, 2013
Last update
Jun 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01322269
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 24, 2011
Start date
Apr 2011
Primary completion
Mar 2012
Last update
Jun 19, 2013

Study contacts

Richard Ghalie, MD, MBA
study director · HemaQuest Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimebutic acid

Start the discussion